DNA-Based Biosensor Helps Better Designing of Anticancer Drugs | WPN World People News

Results of the research can be used by pharmacists in designing and producing new anticancer drugs.

The production of DNA-based biosensors has grown in recent years. However, very few studies have been carried out to understand interactions between the drugs and DNA, although the better understanding of mechanisms of interactions between drug and DNA results in the designing of new efficient drugs and their screening at laboratorial scale.

Mitomycin C (MMC) is one of the most important and commonly-used anticancer drugs. This drug is used in the treatment of stomach, pancreas and large intestine cancers. This research studies interaction of the drug and double string DNA (ds-DNA).

In this study, a biosensor has been designed and its surface has been modified with ds-DNA and carbon nanotubes. The researchers studied the possibility of using electrochemical method in the evaluation of anticancer properties of MMC as a sample of anticancer drugs by using voltammetric and electrochemical impedance spectroscopy.

Results of the research showed that MMC drug does not have any significant effect on DNA, and it needs to be activated to have interaction with DNA. According to the designed tests, this objective can be achieved by reducing the drug in an acidic media.

These types of research will result in the creation of fundamental changes in the diagnosis and determination of the amount of anticancer drugs, cancerous compounds and studying their mechanisms.

Source: Nanotechnology Now